Profound Medical Q2 Earnings Call Highlights

Impact · against what's priced in

Profound Medical shows strong fundamental momentum through superior proposed CMS reimbursement rates and a significant CAD 70 million sales pipeline. While a shipment timing delay caused a Q2 revenue miss, the maintenance of full-year guidance and positive clinical trial data offset short-term operational friction.

PROF+0.40

No priced-in read yet

In context

The proposed 14.9% increase in CMS payments to $15,494 gives TULSA a pricing advantage over robotic radical prostatectomy ($12,300) and Aquablation ($10,797), while a CAD 70 million qualified pipeline provides clear revenue visibility.

Read from the article alone

• earnings
• healthcare
• guidance
• PROF
• cms
• medical devices
• medtech
• reimbursement
• revenue recognition

Search tags